|1.||Denis, Catherine J: 3 articles (03/2013 - 01/2013)|
|2.||Lambeir, Anne-Marie: 3 articles (03/2013 - 01/2013)|
|3.||Hendriks, Dirk: 2 articles (03/2013 - 01/2013)|
|4.||Tsakiris, Ioannis: 2 articles (03/2012 - 04/2008)|
|5.||Nemes, Zoltan: 2 articles (03/2012 - 04/2008)|
|6.||Dezso, Balazs: 2 articles (03/2012 - 04/2008)|
|7.||Soos, Gyorgyike: 2 articles (03/2012 - 04/2008)|
|8.||De Bie, Martine: 1 article (03/2013)|
|9.||Andries, Luc: 1 article (03/2013)|
|10.||Fransen, Erik: 1 article (03/2013)|
01/01/2010 - "Whilst three of these, heme oxygenase-1 (HO-1), aquaporin-1 (AQP-1), and B-cell CLL/lymphoma 2 (Bcl-2) have already been associated with EPO-induced renoprotection, this study for the first time suggests carboxypeptidase M (CPM), dipeptidyl peptidase IV (DPPIV), and cytoglobin (Cygb) to play a role in this process."
03/01/2013 - "The literature was searched using PubMed with the search terms "carboxypeptidase M" and/or "chromosome 12q13-15" eventually combined with general terms related to cancer. "
03/01/2013 - "In the recent literature, carboxypeptidase M (CPM) emerged as a potential cancer biomarker. "
03/01/2013 - "The potential of carboxypeptidase M as a therapeutic target in cancer."
01/16/2013 - "Carboxypeptidase M in apoptosis, adipogenesis and cancer."
03/01/2013 - "Mapping of carboxypeptidase m in normal human kidney and renal cell carcinoma: expression in tumor-associated neovasculature and macrophages."
01/01/2011 - "Tightly regulated by angiotensin-converting enzyme, the intact kinins (BK(2)R agonists) may be processed by carboxypeptidase M/N, generating [des-Arg]-kinins, which activates BK(1)R, a subtype of GPCR that is upregulated by cardiovascular cells during inflammation. "
01/01/1992 - "A reduction of epithelial cell-bonded enzyme (carboxypeptidase M-type or kininase I), produces inflammations by the active intact kinins and the initiation of the alternative activating pathway of complement by active anaphilotoxins, which generate complement cleavage products, containing potential destructive mechanism."
08/01/2012 - "In vitro and in vivo experiments documented that platelet-derived growth factor receptor-β, carboxypeptidase M, carbonic anhydrase 12, receptor activity-modifying protein 1, and low-density lipoprotein receptor-related protein were the 5 specific surface markers regulating various SMPC functions, including migration, extracellular matrix formation, resistance to hypoxia, and anti-inflammation. "
03/01/2012 - "Here, we report that carboxypeptidase-M (CPM), a MA-differentiation marker, is preferentially induced in EPCs of all granuloma types studied, but not in resting MAs. "
01/01/2004 - "Using immunohistochemical evaluation, cells of the granuloma were CD68 (Kp1), carboxypeptidase M and CD3 positive. "
03/01/2012 - "Carboxypeptidase-M is regulated by lipids and CSFs in macrophages and dendritic cells and expressed selectively in tissue granulomas and foam cells."
|5.||Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome)
08/01/2012 - "In severe combined immunodeficiency/nonobese diabetic mice after femoral arterial wire injury, injected human peripheral blood mononuclear cells contributed to substantial amount of neointimal α-smooth muscle actin-positive cells, coexpressing platelet-derived growth factor receptor-β, carboxypeptidase M, carbonic anhydrase 12, receptor activity-modifying protein 1, and low-density lipoprotein receptor-related protein. "
|2.||Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)
|5.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
|6.||Receptor Activity-Modifying Protein 1
|7.||Carboxypeptidase H (Carboxypeptidase E)
|9.||LDL-Receptor Related Protein 1 (LDL-Receptor Related Protein)